{"entity":"abbott-laboratories","id":"ent_abbott-laboratories","name":"Abbott Laboratories","wikidata":"Q306764","page":"https://asof.is/record/abbott-laboratories","summary":"Abbott Laboratories is an American global health care and medical device products company, headquartered in Abbott Park. It reported revenue of $44.33B for the period ended December 31, 2025.","title":"Abbott Laboratories: revenue $44.33B","key_facts":[{"label":"CFO","value":"Philip P. Boudreau","claim":"clm_216BEF8E327D"},{"label":"Headquarters","value":"Abbott Park","claim":"clm_47ECD384B983"},{"label":"Revenue","value":"$44.33B","recorded":"44,328,000,000 United States dollar","note":"to 2025-12-31","claim":"clm_7C1D7352CFA6"},{"label":"Ticker","value":"ABT · NYSE","claim":"clm_E39037FF4684"}],"faq":[{"question":"Where is Abbott Laboratories headquartered?","answer":"Abbott Park."},{"question":"What is Abbott Laboratories's revenue?","answer":"$44.33B for the period ended December 31, 2025."}],"as_of":"2026-11-09","known_by":null,"since":null,"fact_pages":[{"predicate":"cfo","page":"https://asof.is/record/abbott-laboratories/cfo","md":"https://asof.is/record/abbott-laboratories/cfo.md","json":"https://asof.is/v1/entities/abbott-laboratories/cfo"},{"predicate":"headquarters","page":"https://asof.is/record/abbott-laboratories/headquarters","md":"https://asof.is/record/abbott-laboratories/headquarters.md","json":"https://asof.is/v1/entities/abbott-laboratories/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/abbott-laboratories/revenue","md":"https://asof.is/record/abbott-laboratories/revenue.md","json":"https://asof.is/v1/entities/abbott-laboratories/revenue"},{"predicate":"net_income","page":"https://asof.is/record/abbott-laboratories/net_income","md":"https://asof.is/record/abbott-laboratories/net_income.md","json":"https://asof.is/v1/entities/abbott-laboratories/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/abbott-laboratories/operating_income","md":"https://asof.is/record/abbott-laboratories/operating_income.md","json":"https://asof.is/v1/entities/abbott-laboratories/operating_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/abbott-laboratories/quarterly_revenue","md":"https://asof.is/record/abbott-laboratories/quarterly_revenue.md","json":"https://asof.is/v1/entities/abbott-laboratories/quarterly_revenue"}],"products":[],"coverage":{"entity":"abbott-laboratories","name":"Abbott Laboratories","kind":"organization","sources":[{"source":"wikidata","item":"Q306764","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":1800,"ticker":"ABT","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":547,"open":24,"retracted":0,"first":"1888-01-01","predicates":{"shares_outstanding":{"claims":70,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":76,"open":1,"kind":"fact"},"total_assets":{"claims":72,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":42,"open":1,"kind":"fact"},"quarterly_operating_income":{"claims":56,"open":1,"kind":"fact"},"research_and_development":{"claims":9,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":56,"open":1,"kind":"fact"},"total_equity":{"claims":73,"open":1,"kind":"fact"},"revenue":{"claims":19,"open":1,"kind":"fact"},"net_income":{"claims":15,"open":1,"kind":"fact"},"quarterly_research_and_development":{"claims":28,"open":1,"kind":"fact"},"operating_income":{"claims":19,"open":1,"kind":"fact"},"cfo":{"claims":1,"open":1,"kind":"fact"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"headquarters":{"claims":2,"open":2,"kind":"fact"},"x_username":{"claims":1,"open":1,"kind":"identifier"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"registrant_name":{"claims":1,"open":1,"kind":"fact"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"cik":{"claims":1,"open":1,"kind":"identifier"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"website":{"claims":1,"open":1,"kind":"identifier"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":544,"last_added":"2026-11-08","last_checked":"2026-11-09","last_verified":null},{"origin":"wikidata","label":"Wikidata statements that cite a reference URL (wikidata_ingest.py)","claims":3,"last_added":"2026-11-08","last_checked":"2026-11-09","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_73BBEF411CCC","predicate":"agreement","value":"Exact Sciences Corporation","valid_from":"2025-11-19","valid_to":null,"published":"2025-11-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories agreement: Exact Sciences Corporation\", as of 2025-11-19. Claim clm_73BBEF411CCC, https://asof.is/claim/clm_73BBEF411CCC, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000110465925114422/0001104659-25-114422-index.htm.","url":"https://asof.is/claim/clm_73BBEF411CCC","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000110465925114422/0001104659-25-114422-index.htm","tier":"primary","publisher":"SEC EDGAR 8-K","published_at":"2025-11-20T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"On November 19, 2025, Abbott Laboratories, an Illinois corporation (“Abbott”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Exact Sciences Corporation, a Delaware corporation (“Exact Sciences”),","url":"https://www.sec.gov/Archives/edgar/data/1800/000110465925114422/0001104659-25-114422-index.htm"}},{"id":"clm_D623F1D8651F","predicate":"cash_and_equivalents","value":"4,052,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cash and equivalents: 4,052,000,000 United States dollar\", as of 2026-09-30. Claim clm_D623F1D8651F, https://asof.is/claim/clm_D623F1D8651F, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_D623F1D8651F","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_216BEF8E327D","predicate":"cfo","value":"Philip P. Boudreau","valid_from":"2023-01-01","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cfo: Philip P. Boudreau\", as of 2023-01-01. Claim clm_216BEF8E327D, https://asof.is/claim/clm_216BEF8E327D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm.","url":"https://asof.is/claim/clm_216BEF8E327D","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm","tier":"primary","publisher":"SEC EDGAR 10-K","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"Philip P. Boudreau, 53 2024 to present — Executive Vice President, Finance a nd Chief Financial Officer. 2023 to 2024 — Senior Vice President, Finance a nd Chief Financial Officer.","url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm"}},{"id":"clm_DC766CB8ACA6","predicate":"cik","value":"0000001800","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories cik: 0000001800\", undated. Claim clm_DC766CB8ACA6, https://asof.is/claim/clm_DC766CB8ACA6, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_DC766CB8ACA6","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_7EA8A2BEA2BF","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories fiscal year end: 12-31\", undated. Claim clm_7EA8A2BEA2BF, https://asof.is/claim/clm_7EA8A2BEA2BF, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_7EA8A2BEA2BF","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_47ECD384B983","predicate":"headquarters","value":"Abbott Park","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories headquarters: Abbott Park\", undated. Claim clm_47ECD384B983, https://asof.is/claim/clm_47ECD384B983, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_47ECD384B983","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_F43E6397059E","predicate":"headquarters","value":"North Chicago","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories headquarters: North Chicago\", undated. Claim clm_F43E6397059E, https://asof.is/claim/clm_F43E6397059E, accessed 2026-11-10. Source: https://www.med-dept.com/resources/ww2-medical-equipment-manufacturers-and-suppliers/.","url":"https://asof.is/claim/clm_F43E6397059E","accessed":"2026-11-10"},"confidence":0.45,"status":"unverified","assertable":false,"why_not":"low_confidence","superseded_by":null,"sources":[{"url":"https://www.med-dept.com/resources/ww2-medical-equipment-manufacturers-and-suppliers/","tier":"secondary","publisher":null,"published_at":null},{"url":"https://www.wikidata.org/wiki/Q306764","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"page-read","on":"2026-11-09","quote":"Abbott Laboratories, Inc. – North Chicago, Illinois","url":"https://www.med-dept.com/resources/ww2-medical-equipment-manufacturers-and-suppliers/"}},{"id":"clm_349DE9490A94","predicate":"listed_on","value":"NYSE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories listed on: NYSE\", undated. Claim clm_349DE9490A94, https://asof.is/claim/clm_349DE9490A94, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_349DE9490A94","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_76AC317902A6","predicate":"net_income","value":"6,524,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories net income: 6,524,000,000 United States dollar\", as of 2025-12-31. Claim clm_76AC317902A6, https://asof.is/claim/clm_76AC317902A6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_76AC317902A6","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-20"}},{"id":"clm_551396362E4C","predicate":"operating_income","value":"8,053,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories operating income: 8,053,000,000 United States dollar\", as of 2025-12-31. Claim clm_551396362E4C, https://asof.is/claim/clm_551396362E4C, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_551396362E4C","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-20"}},{"id":"clm_0E055280C61A","predicate":"quarterly_net_income","value":"920,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly net income: 920,000,000 United States dollar\", as of 2026-09-30. Claim clm_0E055280C61A, https://asof.is/claim/clm_0E055280C61A, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_0E055280C61A","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_2416CD508AED","predicate":"quarterly_operating_income","value":"1,358,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly operating income: 1,358,000,000 United States dollar\", as of 2026-09-30. Claim clm_2416CD508AED, https://asof.is/claim/clm_2416CD508AED, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_2416CD508AED","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_1E22065402A1","predicate":"quarterly_research_and_development","value":"920,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly research and development: 920,000,000 United States dollar\", as of 2026-09-30. Claim clm_1E22065402A1, https://asof.is/claim/clm_1E22065402A1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_1E22065402A1","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_080974839279","predicate":"quarterly_revenue","value":"13,013,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories quarterly revenue: 13,013,000,000 United States dollar\", as of 2026-09-30. Claim clm_080974839279, https://asof.is/claim/clm_080974839279, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_080974839279","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_78E1BC94DC92","predicate":"registrant_name","value":"ABBOTT LABORATORIES","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories registrant name: ABBOTT LABORATORIES\", undated. Claim clm_78E1BC94DC92, https://asof.is/claim/clm_78E1BC94DC92, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_78E1BC94DC92","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_0537D98543E9","predicate":"research_and_development","value":"2,942,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories research and development: 2,942,000,000 United States dollar\", as of 2025-12-31. Claim clm_0537D98543E9, https://asof.is/claim/clm_0537D98543E9, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_0537D98543E9","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:ResearchAndDevelopmentExpense in 10-K FY2025, filed 2026-02-20"}},{"id":"clm_7C1D7352CFA6","predicate":"revenue","value":"44,328,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories revenue: 44,328,000,000 United States dollar\", as of 2025-12-31. Claim clm_7C1D7352CFA6, https://asof.is/claim/clm_7C1D7352CFA6, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm.","url":"https://asof.is/claim/clm_7C1D7352CFA6","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax in 10-K FY2025, filed 2026-02-20"}},{"id":"clm_7B940234185D","predicate":"shares_outstanding","value":"1,731,941,601 shares","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories shares outstanding: 1,731,941,601 shares\", as of 2026-09-30. Claim clm_7B940234185D, https://asof.is/claim/clm_7B940234185D, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_7B940234185D","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_AB7AA73DD6DF","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_AB7AA73DD6DF, https://asof.is/claim/clm_AB7AA73DD6DF, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_AB7AA73DD6DF","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_5EB4D6DCC26A","predicate":"state_of_incorporation","value":"IL","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories state of incorporation: IL\", undated. Claim clm_5EB4D6DCC26A, https://asof.is/claim/clm_5EB4D6DCC26A, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_5EB4D6DCC26A","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_E39037FF4684","predicate":"ticker","value":"ABT","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories ticker: ABT\", undated. Claim clm_E39037FF4684, https://asof.is/claim/clm_E39037FF4684, accessed 2026-11-10. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800.","url":"https://asof.is/claim/clm_E39037FF4684","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000001800","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_408FF4DCACA7","predicate":"total_assets","value":"108,247,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total assets: 108,247,000,000 United States dollar\", as of 2026-09-30. Claim clm_408FF4DCACA7, https://asof.is/claim/clm_408FF4DCACA7, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_408FF4DCACA7","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_1774BA675DC1","predicate":"total_equity","value":"51,027,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-04","recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories total equity: 51,027,000,000 United States dollar\", as of 2026-09-30. Claim clm_1774BA675DC1, https://asof.is/claim/clm_1774BA675DC1, accessed 2026-11-10. Source: https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm.","url":"https://asof.is/claim/clm_1774BA675DC1","accessed":"2026-11-10"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026070154/0001628280-26-070154-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-04T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-11-04"}},{"id":"clm_E677AE124C79","predicate":"website","value":"https://abbott.com","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories website: https://abbott.com\", undated. Claim clm_E677AE124C79, https://asof.is/claim/clm_E677AE124C79, accessed 2026-11-10. Source: https://www.wikidata.org/wiki/Q306764.","url":"https://asof.is/claim/clm_E677AE124C79","accessed":"2026-11-10"},"confidence":0.45,"status":"unverified","assertable":false,"why_not":"low_confidence","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q306764","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"Abbott Laboratories.","url":"https://www.abbott.com/en-us/homepage"}},{"id":"clm_4CCD509B66A0","predicate":"x_username","value":"AbbottNews","valid_from":"2011-08-22","valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"Abbott Laboratories x username: AbbottNews\", as of 2011-08-22. Claim clm_4CCD509B66A0, https://asof.is/claim/clm_4CCD509B66A0, accessed 2026-11-10. Source: https://www.wikidata.org/wiki/Q306764.","url":"https://asof.is/claim/clm_4CCD509B66A0","accessed":"2026-11-10"},"confidence":0.6,"status":"unverified","assertable":false,"why_not":"unverified","superseded_by":null,"sources":[{"url":"https://www.wikidata.org/wiki/Q306764","tier":"secondary","publisher":"Wikidata","published_at":null}],"evidence":{"by":"own-site","on":"2026-11-08","quote":"https://twitter.com/AbbottNews","url":"https://abbott.com"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{"low_confidence":"Confidence below 0.5, the line the record asserts at.","unverified":"Unverified: one source that is not primary, or a primary source below confidence 0.7. Asserted once a primary source or a second independent domain confirms it."},"checked_by":{"page-read":"its source page states the value and the date","sec-filing":"parsed from the SEC filing","own-site":"the entity's own site names it (a website whose page names the entity, a handle its website links to)"}}}